RenovoRx, Inc. (NASDAQ:RNXT – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $1.11 and traded as low as $1.0350. RenovoRx shares last traded at $1.04, with a volume of 815,148 shares.
Wall Street Analyst Weigh In
A number of equities analysts have commented on RNXT shares. Weiss Ratings raised RenovoRx from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 2nd. Wall Street Zen cut RenovoRx from a “hold” rating to a “sell” rating in a research report on Monday, November 9th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, RenovoRx currently has a consensus rating of “Moderate Buy” and an average price target of $8.50.
Check Out Our Latest Research Report on RNXT
RenovoRx Price Performance
The company’s 50 day moving average price is $1.45 and its two-hundred day moving average price is $1.11. The stock has a market capitalization of $50.18 million, a PE ratio of -3.35 and a beta of 1.12.
RenovoRx (NASDAQ:RNXT – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). RenovoRx had a negative return on equity of 133.49% and a negative net margin of 469.02%. The business had revenue of $1.07 million for the quarter, compared to analyst estimates of $1.06 million. Analysts forecast that RenovoRx, Inc. will post -0.28 earnings per share for the current year.
Institutional Inflows and Outflows
An institutional investor recently bought a new stake in RenovoRx stock. T3 Companies LLC bought a new position in RenovoRx, Inc. (NASDAQ:RNXT – Free Report) in the third quarter, according to its most recent disclosure with the SEC. The firm bought 96,800 shares of the company’s stock, valued at approximately $151,000. T3 Companies LLC owned about 0.21% of RenovoRx as of its most recent SEC filing. Institutional investors and hedge funds own 3.10% of the company’s stock.
RenovoRx Company Profile
RenovoRx, Inc. is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its approach is designed to deliver therapy directly to targeted tissue through the arteries that supply it, with the goal of limiting exposure to the rest of the body. The company’s platform includes RenovoCath, a catheter cleared by the U.S. Food and Drug Administration for the localized infusion of therapeutic agents. RenovoRx is also evaluating RenovoGem, a combination of its delivery approach and the chemotherapy drug gemcitabine, for patients with locally advanced pancreatic cancer.
Read More
- Five stocks we like better than RenovoRx
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for RenovoRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RenovoRx and related companies with MarketBeat.com's FREE daily email newsletter.
